24/04/2014 03:16:29 Free Membership Login

Cubist News (NASDAQ:CBST)

DateTimeSource
Headline
04/23/20148:30AMBWCubist and Cambridge Science Festival Announce 2014 Germ Challenge Science Contest Winners
Teens Submit More than 20 Video Entries Describing Germs Cambridge Science Festival and Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the winners of the 2014 Germ Challenge, a contest designed to engage young people in science by inviting them to develop educational and creative videos that demonstrate their... More...>>
04/22/20144:00PMBWCubist Pharmaceuticals Reports First Quarter 2014 Financial Results
Total Net Revenues of $261.2 Million, Up 14% Over Q1 2013; U.S. CUBICIN Net Revenues of $212.2 Million, Up 5% Over Q1 2013 Non-GAAP Adjusted Operating Income of $18.8 Million; GAAP Operating Income of $28.3 Million Non-GAAP Diluted EPS of $0.10; GAAP Diluted EPS of $0.30 Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today... More...>>
04/21/20148:30AMBWCubist Announces Submission of New Drug Application for Investigational Antibiotic Ceftolozane/tazobactam
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of its investigational antibiotic ceftolozane/tazobactam for the treatment of Complicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal... More...>>
04/18/201411:59AMBWCubist Pharmaceuticals Issues Voluntary Nationwide Recall of One Lot of CUBICIN (daptomycin for injection) 500 mg in 10 mL si...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling one lot of CUBICIN® (daptomycin for injection) to the user level due to the presence of particulate matter, reported via customer complaint and identified as glass particles, found in a single vial from this lot, produced by a contract... More...>>
04/15/20148:00AMBWCubist to Announce First Quarter 2014 Financial Results on Tuesday, April 22, 2014
Earnings Conference Call & Webcast at 5:00 pm ET Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its first quarter 2014 financial results at 4:00 p.m. ET on Tuesday, April 22, 2014. In connection with this announcement, Cubist will host a conference call and live audio webcast presentation at 5:00 p.m. ET that... More...>>
04/14/201410:00AMZACKSWill Johnson & Johnson (JNJ) Miss This Earnings Season? - Analyst Blog
Johnson & Johnson (JNJ) is scheduled to report first quarter 2014 results before the opening bell on Apr 15. Last quarter, Johnson & Johnson had posted an earnings surprise of +3.33%. Let’s see how things are shaping up for this announcement. Factors at Play Johnson & Johnson has delivered positive earnings... More...>>
04/01/20148:00AMBWCubist Appoints Robert J. Perez to Board of Directors
Three Long-Serving Directors to Retire Cubist (NASDAQ: CBST) today announced the appointment of Robert J. Perez to its Board of Directors. Since 2012, Mr. Perez has served as Cubist’s President and Chief Operating Officer (COO). The Company also announced that in accordance with its Corporate Governance Guidelines regarding... More...>>
03/31/20141:40PMBWFDA Advisory Committee Unanimously Recommends Approval of Cubist’s SIVEXTRO™ (Tedizolid Phosphate) as Treatment for Serio...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today that the U.S. Food and Drug Administration (FDA) Anti-Infective Drugs Advisory Committee (AIDAC) voted to recommend approval of Cubist’s investigational antibiotic SIVEXTRO™ (tedizolid phosphate). In the unanimous 14 - 0 decision, the AIDAC found that substantial... More...>>
03/26/20142:17AMZACKSPharma & Biotech Stock Outlook - March 2014 - Industry Outlook
The pharmaceutical sector has been slowly but steadily recovering from the impact of the patent cliff being faced by several companies over the past few years. The worst of the patent cliff is over and the NYSE ARCA Pharmaceutical Index (^DRG) is up 21.4% over the last year. So far in 2014, the index is up 6.9%. Several... More...>>
03/26/20142:17AMZACKSPharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
The pharmaceutical sector has been slowly but steadily recovering from the impact of the patent cliff being faced by several companies over the past few years. The worst of the patent cliff is over and the NYSE ARCA Pharmaceutical Index (^DRG) is up 21.4% over the last year. So far in 2014, the index is up 6.9%. Several... More...>>
02/27/20144:02PMBWCubist: Antrag auf Marktzulassung von Tedizolid von EMA zur Prüfung angenommen
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) meldete heute, dass die Europäische Arzneimittelbehörde (EMA) den Antrag auf Marktzulassung (Marketing Authorization Application, MAA) des Unternehmens für das Prüfantibiotikum Tedizolidphosphat zur Prüfung angenommen hat. Cubist beantragt die Zulassung von Tedizolid zur... More...>>
02/27/20144:02PMBWCubist annonce que l'Agence européenne du Médicament (AEM) a accepté de réviser la demande de commercialisation du Tedizo...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) a annoncé aujourd'hui que l'Agence européenne du Médicament (AEM) avait accepté de réviser la demande d'homologation de mise sur le marché (AMM) de son antibiotique expérimental, le phosphate de tedizolid. Cubist attend l'approbation du tedizolid pour le traitement des... More...>>
02/27/20147:38AMBWCubist Announces EMA Acceptance of Tedizolid Marketing Authorization Application for Review
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the European Medicines Agency (EMA) has accepted for review the Company’s Marketing Authorization Application (MAA) for its investigational antibiotic tedizolid phosphate. Cubist is seeking approval of tedizolid for the treatment of complicated skin and... More...>>
02/13/20146:00AMBWCubist & Cambridge Science Festival Launch “Germ Challenge” Science Contest
Students Demonstrate Knowledge of Germs through Exciting Videos Aimed at Fifth Grade Audience Cambridge Science Festival and Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today launched the 2014 “Germ Challenge,” a contest designed to engage young people in science by inviting them to create educational and creative... More...>>
02/10/20148:00AMBWCubist to Present at February Investor Conferences
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that company management will discuss the company’s business activities, financial outlook, at the 2014 RBC Capital Markets’ Global Healthcare Conference in February. Details are below. PRESENTER: Michael Tomsicek, SVP & CFO & Eileen C. McIntyre, VP... More...>>
01/23/20144:00PMBWCubist Reports Fourth Quarter and Full Year 2013 Financial Results; Provides 2014 Revenue Guidance
Full Year Total Net Revenues of $1.1 Billion, Up 14% Over 2012 Full Year Non-GAAP Adjusted Operating Income of $189.7 Million; Full Year GAAP Operating Income of $26.4 Million Full Year Non-GAAP Diluted EPS of $1.45; Full Year GAAP Diluted EPS of $(0.27) Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results... More...>>
01/13/20147:30AMBWCubist Announces Fourth Quarter/Full-Year 2013 Revenues; Provides Pipeline Update
2013 Total Net Revenues of $1.1 Billion, Up 14% Over 2012; Q4 Total Net Revenues of $299.7 Million, Up 22% Over 2012 CUBICIN Achieves Blockbuster Status with 2013 Worldwide Sales of over $1 Billion 2013 U.S. CUBICIN Net Product Revenues of $908.0 Million, Up 12% Over 2012; Q4 U.S. CUBICIN Net Product Revenues of $248.9... More...>>
01/10/20146:59PMBWCubist reicht Antrag für klinische Prüfungen zur Einleitung der ersten Studie am Menschen des von Cubist entdeckten Beta-La...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) meldete heute die Einreichung eines Antrags für klinische Prüfungen (Clinical Trial Application, CTA) bei der zuständigen niederländischen Behörde und Ethikkommission, um die erste Studie am Menschen von CB-618 in den Niederlanden einzuleiten. CB-618 wurde von Cubist entdeckt... More...>>
01/10/20146:30PMBWCubist présente une demande d'essais cliniques pour le lancement d'une étude de première administration chez l'homme du CB...
Cubist Pharmaceuticals, Inc. (NASDAQ : CBST) a annoncé aujourd'hui avoir présenté à l'autorité compétente et au Comité de déontologie des Pays-Bas une demande d'essais cliniques pour le lancement aux Pays-Bas d'une étude de première administration chez l'homme du CB-618. Découvert par Cubist, le CB-618 est un... More...>>
01/10/201411:05AMBWCubist Submits Clinical Trial Application to Initiate First-in-Human Study of CB-618—A Beta-Lactamase Inhibitor Discovered ...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it submitted a Clinical Trial Application (CTA) to the Dutch Competent Authority and Ethics Committee to initiate a first-in-human study of CB-618 in the Netherlands. Discovered by Cubist, CB-618 is a novel, broad-spectrum beta-lactamase inhibitor (BLI) investigational... More...>>


NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq cbst140424 03:16